Business Wire

JETRO Osaka (Japan External Trade Organization): Making an Innovation Movement From Osaka

Share

The Kansai region, which includes unique cities of Osaka, Kobe and Kyoto, is a massive market with a population of 24.65 million people and a GDP of approximately 100.05 trillion yen. It equals the metropolitan area centered on Tokyo as a site for business and plays the central role in the economy of Western Japan.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220124005319/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Succeed Together in Japan and Beyond (Graphic: Business Wire)

In this region, particularly on the Osaka Gulf Coast, there is a cluster of companies and research institutes related to the environmental and new energy industries. Also, throughout Osaka City, bio-related pharmaceutical companies and food manufacturers gather as well as the chemical and medical equipment companies.

[Source] JETRO Investing in Japan “Osaka City”
https://www.jetro.go.jp/en/invest/region/data/osaka-city.html
O-BIC “Industry of Osaka”
https://o-bic.net/e/attractive/

As the host city of the next World Expo in 2025, Osaka has been a hot spot for startups attracting various companies and people from all over the world.

Boosting up innovation movement, Global Innovation Conference Hack Osaka Executive Committee* will host Startup Business Meetings from February 8th (Tue) to 9th (Wed), co-organized by Osaka Prefecture, as one of the programs of Annual Global Innovation Conference, Hack Osaka 2022.

* The committee composes of Osaka City, Urban Innovation Institute, JETRO Osaka, and Osaka Business Development Agency.

In 2022, with the themes of “Next-Generation Air Mobility” and “Infrastructure”, a talk session between companies engaging in eVTOL development, reverse pitch by corporations in Kansai region, and global pitch contest Hack Award 2022 are waiting to be streamed.

Hack Osaka 2022
Date: Thursday, Feb. 10th, 2022 1 p.m. –7 p.m. (JST)
Registration:https://www.innovation-osaka.jp/hackosaka/en/index.php

Startup Business Meetings 2022
Date: Tuesday, Feb. 8th to Wednesday, Feb. 9th, 2022 9 a.m. – 8 p.m. (JST)
Information:https://www.innovation-osaka.jp/hackosaka/en/business-meeting.php

[List of Startups]

UrbanChain Group Limited

Hong Kong

(Smart parking)

Autofleet

Israel

(Fleet management)

HeyCharge GmbH

Germany

(EV charge in in-door environment)

H3 Dynamics

Singapore

(Hydrogen propulsion drone × AI)

MobyFly

Switzerland

(Zero-emission hydrofoil)

FLYING WHALES

France

(Air freight solution with loads of 60t)

Sharper Shape Inc.

USA

(Digital twin for utility infrastructure)

INFINITE FOUNDRY

Brazil

(3D Digital twin for industries)

Asilla, Inc.

Japan

(AI security system)

NanoLock security

Israel

(Zero-trust security for IoT devices)

BYSTAMP

France

(Digital stamp)

Falkonry Inc.

USA

(Fact-based insights for manufacturing with AI)

Innoviz Technologies

Israel

(3D LiDAR)

Materna IPS GmbH

Germany

(Biometrics × passenger processing)

Verily Vision

Thailand

(Logistics automation at ports, warehouses, factories)

Details of Startups: https://www.innovation-osaka.jp/hackosaka/assets/doc/2022-participants/en/all-business2022-en.pdf

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

[Inquiries]
Global Innovation Conference Hack Osaka Executive Committee (JETRO Osaka)
Aki Hirahata
TEL: +81 6-4705-8603 (Mon – Fri 9:30 a.m. – 5:30 p.m. Closed during national holidays)
E-mail: osd@jetro.or.jp

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CARVYKTI ® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma26.5.2022 09:10:00 CEST | Press release

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that the European Commission (EC) has granted conditional marketing authorization of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD) and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy. Legend Biotech entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc. (Janssen) to develop and commercialize cilta-cel in December 2017. CARVYKTI® is a chimeric antigen receptor T-cell (CAR-T) therapy featuring two B-cell maturation antigen (BCMA)-targeting single domain antibodies.1 CAR-T therapy is specifically developed

European Commission Grants Conditional Approval of CARVYKTI ® (Ciltacabtagene Autoleucel), Janssen’s First Cell Therapy, for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma26.5.2022 09:00:00 CEST | Press release

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) granted conditional marketing authorisation of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy. In December 2017, Janssen Biotech, Inc. (Janssen) entered into an exclusive worldwide license and collaboration agreement with Legend Biotech USA, Inc. to develop and commercialise cilta-cel.2 “Patients who have relapsed, or for whom treatment regimens have stopped working after experiencing the three major drug classes, typically face poor survival. Despite recent innovation, new therapeutic approaches are still needed,” said Maria-Victoria Mateos, M.D., Ph.D., Consultant Physician in Haematology,

SCREEN Increases Efforts to Reduce the Environmental Impact of the Semiconductor Industry26.5.2022 06:30:00 CEST | Press release

SCREEN Semiconductor Solutions Co., Ltd. (SCREEN SPE), a subsidiary of SCREEN Holdings Co., Ltd., has announced it will increase its efforts to reduce the company’s environmental overall impact. The SCREEN Group is committed to both achieving a sustainable global society and to improving its sustainable value (social value) and has formulated a medium-term management plan titled Sustainable Value 2023 targeting these goals. The plan identifies specific issues in each of the environmental, social, and governance (ESG) fields. Concerning the environment, SCREEN is working to provide products and services that actively contribute to the reduction of ecological burden. Its efforts include improving the environmental performance of its products, reducing the effects of its business activities on climate change, promoting effective utilization of water resources, increasing recycling of products and parts, and helping to preserve biodiversity. Concretely, SCREEN SPE seeks to reduce the impac

Lenovo Group: Full Year Financial Results 2021/2226.5.2022 06:19:00 CEST | Press release

Lenovo Group (HKSE: 992) (ADR: LNVGY) today announced record fiscal year results for the Group, with historic highs for both profit and revenue. Annual net income reached the US$2 billion mark, up 72% year on year, with revenue growing by US$10 billion for the second year running to over US$71 billion. All main business groups were profitable for the full fiscal year - with strong growth momentum in mobile, infrastructure, and solutions and services businesses. Lenovo successfully overcame macro-environmental challenges and demonstrated both agility and resilience as it navigated industry-wide supply shortages, pandemic disruption, geopolitical uncertainties, and higher inflation to deliver a record year. The digital and intelligent transformation trend continues to accelerate, presenting the Group with strong growth opportunities. More than 50% of companies now have digitalization as part of their corporate strategy, up from just over one third two years ago. The hybrid work model is

Exscientia Business Update for First Quarter 202225.5.2022 22:01:00 CEST | Press release

Exscientia plc (Nasdaq: EXAI) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220525005906/en/ Recent advancements in the Company’s pipeline, collaborations, and operations, as well as financial results for the first quarter 2022, are summarised below. In addition, Exscientia will host a conference call Thursday, May 26 at 1:30 p.m. BST / 8:30 a.m. ET to provide an overview of the Company's precision medicine platform. "We started 2022 by commencing a groundbreaking collaboration with Sanofi to develop a pipeline of AI-designed medicines utilising the breadth of our end-to-end platform of AI-driven capabilities from target prioritisation, to drug engineering and patient selection. At this year's American Association of Cancer Research (AACR) Annual Meeting, we highlighted our advancements in this area, including how AI-enabled drug design can help create drug candidates for challenging targets in oncology. In addition, we sho

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom